Key facts, as of
As of October 8, 2026, Align Technology (ALGN) trades at $139.87, up 7.2% over the past year. Its 52-week range runs from $124.91 to $200.44; the price is 30.2% below that high. It is 81.0% below its all-time high of $737.45, reached in September 2021. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +55.0%, against +312.9% for the S&P 500 (SPY). It sits 17.7% below its 200-day average of $170.00, the usual sign of a long-term downtrend. Its 30-day volatility is 28.5% annualized, which we rate medium risk. It has a trailing P/E of 24.3.
Cite: Portfolio Terminal, "Align Technology (ALGN) stock analysis", 2026-10-08. https://portfolio-terminal.com/analyse/algn
Where it trades today
trading 20% of the way up its 52-week range
How the price has moved
How far it is from its record
Align Technology (ALGN) is 81.0% below its all-time high of $737.45, reached in September 2021. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +55.0%, against +312.9% for the S&P 500 (SPY).
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- ALGN is valued near its sector range at 24.3x earnings versus 22.0x for peers, so the next move likely needs a real earnings or guidance catalyst.
- Recent realized volatility is running around 28.5%, above the sector norm of 22.0%, so position sizing matters more than usual.
- ALGN remains in a bearish short-term trend and sits 30.2% below its high, which raises the bar for any thesis that depends on fast multiple expansion.
Portfolio Use Case
- ALGN is more useful for investors comparing conviction names inside healthcare than for someone looking for a passive “set and forget” holding.
- This name works better as a satellite or higher-conviction growth position because it can amplify market swings in both directions.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A reset in earnings expectations or a faster peer catch-up could compress the premium valuation currently embedded in ALGN.
- A recovery in price alone would not be enough to improve the view; the thesis needs confirmation from improving business or valuation signals.
- Volatility is already above the sector norm, so even a correct long-term thesis can be painful if the position size is too aggressive.
Methodology
- Price, market cap, beta, yield, and liquidity fields for ALGN come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for ALGN. Last refresh: Oct 8, 2026, 10:10 AM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What Align Technology does
Align Technology, Inc. provides Invisalign clear aligners, Vivera retainers, and iTero intraoral scanners and services in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers Invisalign comprehensive package to treat adults and teens malocclusion and features, and orthodontic needs of teenage or younger patients; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients between the ages of six and ten years with a mixture of primary/baby and permanent teeth. This segment also provides Invisalign express, Invisalign lite, and Invisalign moderate; Invisalign Go, Invisalign Go express, and Invisalign Go Plus;…
Employees
20,435
Industry
Medical Instruments & Supplies
Headquarters
Tempe, United States
What analysts expect
ALGN carries a buy consensus from 14 analysts, with an average price target of $201.71 versus $139.87 today (+44.2%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
ALGN generated $4.14B in trailing revenue (4.3% year over year), with a 10.0% net margin, and $594.11M of free cash flow, supported by $981.75M of net cash.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $4.03B | $2.71B | $585.31M | $410.35M | $5.66 | $490.78M |
| 2024 | $4.00B | $2.80B | $671.76M | $421.36M | $5.63 | $622.65M |
| 2023 | $3.86B | $2.71B | $656.65M | $445.05M | $5.82 | $608.06M |
| 2022 | $3.73B | $2.63B | $654.05M | $361.57M | $4.62 | $276.83M |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
ALGN is in 5 of the 30 ETFs we track. It weighs most in XLV: 0.16% of the fund, holding #56 of 62.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
ALGN beside the healthcare names it is usually measured against.
What the chart is saying
In a downtrend, with $130.95 the next floor.
downtrend- Price is 11.7% below its 50-day average and 17.7% below its 200-day.
- The 50-day crossed below the 200-day on 2026-09-09 (a “death cross”).
- RSI at 33 is neither stretched nor washed out.
- The nearest ceiling is $151.18 (+8.1%), the nearest floor $130.95 (-6.4%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
Is ALGN a good investment in 2026?
Align Technology trades at a P/E ratio of 24.3, with medium volatility (28.5% annualized). Recent trend shows weakness.
What is the risk level of ALGN?
Based on 30-day volatility of 28.5%, ALGN has MEDIUM risk. Beta of 1.67 indicates higher sensitivity to market movements than average.
Does ALGN pay dividends?
Align Technology currently does not pay a regular dividend.
How far is ALGN from its all-time high?
Align Technology is 81.0% below its all-time high of $737.45, reached in September 2021. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +55.0%, against +312.9% for the S&P 500 (SPY).
Which ETFs hold ALGN?
5 of the 30 popular ETFs we track hold Align Technology. The largest weights: XLV (0.16%), VOO (0.02%), VTI (0.01%), SPY (0.01%) and IVV (0.01%). Measured on each issuer's full holdings file, dated August 31 to September 24, 2026.
How much of VOO is ALGN?
0.02%, as of August 31, 2026: ALGN is holding #474 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $0.16 in Align Technology.
What is the analyst price target for ALGN?
The average analyst price target for Align Technology (ALGN) is $201.71 based on 14 analyst estimates, about 44.2% above the current price of $139.87. The published range runs from $155.00 to $235.00.
How much revenue does ALGN generate?
Align Technology reported $4.14B in trailing twelve-month revenue. Revenue growth is running at 4.3% year over year. Net margin sits at 10.0%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare ALGN with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.